Discovery/R&D

  1. Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D. 12/12/2022

    While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger. Osteoarthritis, or OA, is a chronic, progressive joint disease that affects over 30 million people in the United States. On this episode of the Business of Biotech, we catch up with Xalud Chief Medical Officer Howard Rutman, M.D., MBA for a discussion on the company's late-stage plasmid DNA gene therapy that's showing promise in OA and other chronic inflammatory conditions. 

  2. Digital Transformation In Cell Therapy with Organicell Drs. Mari Mitrani & Michael Bellio 5/3/2021

    Drs. Mari Mitrani, CSO and Michael Bellio, Laboratory Director are young pioneers in the study of the therapeutic potential of exosomes. Their research leans heavily into the digital realm, leveraging computational biology, bioinformatics, large-scale sequencing, proteomics, and mass spectrometry to analyze perinatal tissue-secreted exosomes and their impact on a host of indications the company is exploring. On this episode of The Business Of Biotech, Drs. Mitrani and Bellio offer insight into the digital discovery and manufacturing automation technologies in use at Organicell.

  3. mRNA Vaccine Platforms With Combined Therapeutics' Dr. Romain Micol 11/29/2023

    Combined Therapeutics President & CEO Dr. Romain Micol is operating his company in a very noisy space, where hundreds of new biotechs have popped up on the coattails of a COVID-driven renewal of interest in mRNA vaccines. Micol recognizes that noise and the competition it brings for capital and mindshare. 

  4. Expanding The Proteome with ProFound's John Lepore, M.D. 7/28/2024

    Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question:  What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome.

  5. The Face Of African Biotech with Adrienne Leussa, Ph.D. 6/7/2023

    Dr. Adrienne Leussa is one of our favorite follows. If the booming biotech scene on an incredibly diverse continent of 1.2 billion people interests you, she should be one of your faves, too.

  6. The AAV Vector Challenge With Selecta's Dr. Carsten Brunn 1/12/2021

    The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

  7. Gene Therapies For Ocular Disease With SparingVision's Stéphane Boissel 3/28/2022

    Since assuming the President and CEO role at SparingVision in August 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company'S foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind his vigorous allegiance to internal development.

  8. Building A DNA Delivery System With Poseida Tx CEO Eric Ostertag, M.D., Ph.D. 9/27/2021

    Eric Ostertag, M.D., Ph.D., wanted to launch a biotech. When University of Pennsylvania department heads said no to a licensing deal for lack of a CEO, Dr. Ostertag convinced them he could run the company. Many bold moves later, Dr. Ostertag is founder and CEO at Poseida Therapeutics, a company that's doing things never seen before in the field of CAR T-cell and gene therapies for multiple myeloma and prostate cancer. On this week's episode of The Business of Biotech, Dr. Ostertag gives us a tour of the architecture supporting Poseida's unique 3-tiered development and manufacturing platform.

  9. Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D. 8/27/2025

    On this week's Business Of Biotech episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks.

  10. Building A Biotech Around Your Therapeutic Platform 8/13/2020

    Heat Biologics founder and CEO Jeff Wolf took a creative approach to building his company. With the science behind his company's platform to activate immune responses against pathogenic or cancer antigens in place, he proceeded to structure the organization and its people in a strategic fashion to support that platform. Learn how he did it–and how Heat's management philosophy is driving innovation and efficiency there–on this episode of The Business Of Biotech: Summer Executive Sessions.